Coman Mindru Popescu has successfully represented Chenda Filoteia against Romania's Ministry of Health, National Health Insurance House, and National Agency for Medicines and Medical Devices in a dispute over national health insurance coverage of the usage of Avastin for the glioblastoma therapeutic indication.
According to the firm, “the Pitesti Court of Appeal ordered the National Agency for Medicines and Medical Devices to initiate, ex officio, the procedure for the assessment of medical technologies in order to include the Bevacizumab medicine (trade name Avastin) in the list of international non-proprietary names corresponding to the medicines from which the insured persons benefit under medical prescription for the therapeutic indication glioblastoma.”
According to the public record, the court also obligated the three defendants to pay the plaintiff RON 11,720.
CMP Law did not respond to our inquiry on the matter.
